You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Randomized Prospective Phase II Clinical Trial of NVX in Association with Chemoradiation of Glioblastoma

    SBC: NUVOX PHARMA, L.L.C.            Topic: 102

    Glioblastoma multiforme GBM is a malignant primary brain tumor affecting about new cases per year in the U S Average survival is only about months Radiation RT is most commonly administered as fractions of Gray each over weeks with concomitant temozolomide TMZ GBM tumors are hypoxic The primary mechanism of RT is creation of singlet oxygen hypoxia within GBM adversel ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  2. An Integrated Microarray Printing and Detection System

    SBC: BIOSENSING INSTRUMENT INC            Topic: 400

    DESCRIPTIONprovided by applicantMicroarray technology has dramatically advanced the study of protein interactions leading to discovery and validation of new biomarkers and therapeutic drugsTypicallyprotein microarrays are pre spotted with target molecules in one device and then tested with probe molecules using another deviceDuring each testing cyclethe entire microarray becomes exposed to the pro ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Enhancing cytarabine efficacy in leukemia through CDK inhibition

    SBC: SENEX BIOTECHNOLOGY            Topic: 102

    Acute myeloid leukemia AML is the most common acute leukemia in adults with new cases annually in the US A deoxycytidine nucleoside analog Cytarabine AraC is the principal chemotherapeutic agent used in AML AraC containing chemotherapeutic regimens induce complete remission in of newly diagnosed AML patients but a substantial minority of leukemias is intrinsically resistant t ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Novel injectable resiquimod formulation for treatment of metastatic cancers

    SBC: Curebiotech, Inc.            Topic: NCI

    PROJECT SUMMARY Malignant melanoma is one of the most aggressive types of skin cancer causing a large majority of skin cancer related deaths worldwide Recently there have been staggering breakthroughs with the advent of drugs that act on checkpoint inhibitors These are paradigm shifting immunotherapeutic agents not only for melanoma but for cancers in general because they harness the bodyan ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Inexpensive, sensitive and specific, point-of-care diagnostic for bacterial infections in the central nervous system

    SBC: CNine Biosolutions            Topic: NIAID

    The objective of this Phase I application is to develop and assess a sMAC lateral flow assay diagnostic tool for bacterial meningitisBMDevelopment of rapidhighly sensitive and specific clinical diagnostic for bacterial infections in the central nervous systemCNSsuch as BM and shunt infectionthat are easy to use and cost effectivewould significantly improve healthcare in the US and worldwideWe have ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. CRISPR Cas Systems Delivered by Targeted Nanoparticles to Eradicate Herpesvirus Pathogens

    SBC: Theragnostic Technologies Inc.            Topic: NIAID

    Abstract Herpesviruses are chronic pathogens that infect for life there is no cure years since the discovery of the first tumor virus the herpesvirus Epstein Barr virus EBV there exist no specific antivirals for EBV during its latency phase and there are no vaccines The same holds true for most of the other eight human herpesviruses This proposal aims to develop novel tools to eradicat ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. A Nitric Oxide Polymer Platform for the Prevention and Treatment of Infected Wounds

    SBC: IFYBER, LLC            Topic: NIAID

    This proposed SBIR research effort will lay the foundation for commercializing a new class of biomaterial for the prevention and treatment of infected skin wounds thereby enhancing patient health through improved patient outcome and reduced patient morbidity Specifically we will focus on evaluating and developing a biomaterial comprised of a nitric oxide NO releasing based on a commonly used ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Assembled Porous Silica Membranes for Biomolecule SPE

    SBC: ADVANCED MATERIALS TECHNOLOGY, INC.            Topic: 400

    Abstract Life sciences research and other critical bioanalytical applications would strongly benefit from faster and higher efficiency sample preparation processes Sample preparation before high resolution analytical methods such as HPLC or LC MS can require effort and cost nearly equivalent to the actual sample analysis and data reduction Often sample preparation for proteomic glycoproteom ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Fluorescent reporters for real time single cell Pol III transcription measurement

    SBC: Lucerna Inc.            Topic: 400

    SUMMARY RNA polymerase III Pol III is increasingly recognized as an important drug target and a rapidly developing area of academic research Pol III is responsible for generating RNAs that are critical for cell growth such as tRNAs certain rRNAs and various noncoding RNAs involved in processes such as mRNA splicing These RNAs are required for cell growth proliferation and differentiation ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. A phosphopeptide multiplex PRM mass spectroscopic biomarker assay for PAH

    SBC: Pulmokine, Inc.            Topic: NHLBI

    The purpose of this phase SBIR grant is to develop a quantitative phosphopeptide biomarker assay for pulmonary arterial hypertension PAH The commercial product will consist of a kit of stable isotopically labeled internal standards of a selected set of phosphopeptides either up or down regulated in PAH The set of stable isotopically labeled peptides will be used in a parallel reaction monito ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government